Conferences: SIRS

SIRS

SIRS 2023 

Safety and Efficacy of KarXT in Patients With Schizophrenia in the Randomized, Double-Blind, Placebo-Controlled, Phase 3 EMERGENT-2 and EMERGENT-3 Trials 

SIRS 2023 

The Role of M1 and M4 Muscarinic Receptors in Cognitive Performance 

SIRS 2022

The Muscarinic Agonist Xanomeline Demonstrates Standalone Activity and Augments Clinical Antipsychotics in Rodent Behavioral Models of Psychosis

SIRS 2022

Acetylcholine as a Regulator of Dopamine Pathways: Rationale for Selective Muscarinic Agonists as Candidates for Antipsychotic Drug Development

SIRS 2022

The Potential of M1 Agonists to Treat Cognitive Impairment: Evidence From a Phase 2 Study of KarXT in Schizophrenia (EMERGENT-1)

SIRS 2022

A Phase 3 Placebo-Controlled Study Evaluating the Safety and Efficacy of Adjunctive KarXT in Patients With Inadequately Controlled Schizophrenia Symptoms: Clinical Rationale and Design (ARISE Study)

SIRS 2021

The M1/M4 Agonist Xanomeline in Combination With Trospium Is Effective for Acute Treatment of Schizophrenia: PANSS Responder and PANSS 5-Factor Analyses of a Phase 2 Placebo-Controlled Inpatient Trial

SIRS 2020

KarXT (Xanomeline, a Muscarinic Agonist Plus Trospium, a Peripheral Muscarinic Antagonist) Is Superior to Placebo in Patients With Schizophrenia: Phase 2 Clinical Trial Results